Figure 15. Ovarian cancer: mitochondrial-based companion diagnostics for personalized cancer therapy.

In this diagram, mitochondrial-based diagnostics would be used to separate ovarian cancer patients into higher-risk and lower-risk groups. Then, patients with high levels of mitochondrial markers in their primary tumor (“bad prognosis”) would be treated with mitochondrial-based therapies (such as “Doxycycline”), as an add-on to the standard of care, to prevent tumor progression and increase overall survival.